- Home
- CGEN vs ALEC Comparison
CGEN vs ALEC Comparison
Compare CGEN & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- ALEC
- Stock Information
- Founded
- CGEN 1993
- ALEC 2013
- Country
- CGEN Israel
- ALEC United States
- Employees
- CGEN 74
- ALEC N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CGEN Health Care
- ALEC Health Care
- Exchange
- CGEN Nasdaq
- ALEC Nasdaq
- Market Cap
- CGEN 125.3M
- ALEC 124.0M
- IPO Year
- CGEN 2000
- ALEC 2019
- Fundamental
- Price
- CGEN $1.38
- ALEC $2.90
- Analyst Decision
- CGEN
- ALEC Buy
- Analyst Count
- CGEN 0
- ALEC 8
- Target Price
- CGEN N/A
- ALEC $4.50
- AVG Volume (30 Days)
- CGEN 238.3K
- ALEC 1.3M
- Earning Date
- CGEN 11-11-2025
- ALEC 11-05-2025
- Dividend Yield
- CGEN N/A
- ALEC N/A
- EPS Growth
- CGEN N/A
- ALEC N/A
- EPS
- CGEN N/A
- ALEC N/A
- Revenue
- CGEN $22,144,000.00
- ALEC $81,130,000.00
- Revenue This Year
- CGEN N/A
- ALEC N/A
- Revenue Next Year
- CGEN $159.40
- ALEC $196.86
- P/E Ratio
- CGEN N/A
- ALEC N/A
- Revenue Growth
- CGEN N/A
- ALEC 46.77
- 52 Week Low
- CGEN $1.13
- ALEC $0.87
- 52 Week High
- CGEN $2.66
- ALEC $6.37
- Technical
- Relative Strength Index (RSI)
- CGEN 41.92
- ALEC 64.58
- Support Level
- CGEN $1.39
- ALEC $2.71
- Resistance Level
- CGEN $1.47
- ALEC $3.00
- Average True Range (ATR)
- CGEN 0.06
- ALEC 0.20
- MACD
- CGEN -0.00
- ALEC 0.00
- Stochastic Oscillator
- CGEN 33.33
- ALEC 77.27
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.